Skip to content

    ERIS Lifescience

    ERISGood
    Healthcare·25 Oct 2024
    Management Summary

    ERIS delivered a strong Q2 FY25 with significant revenue and EBITDA growth driven by the integration of Biocon's business and robust manufacturing execution. While the organic base business saw a temporary slowdown in Q2 (4% growth), management reaffirmed full-year guidance, banking on a 'new-launch heavy' second half. The company is successfully deleveraging its balance sheet and expanding margins through in-house manufacturing shifts in Derma and Insulin segments.

    Highlights

    7

    • Consolidated revenue grew 47% YoY to ₹741 crores; H1 revenue reached ₹1,461 crores (+50% YoY).

    • Consolidated EBITDA stood at ₹265 crores with a 35.7% margin, representing 46% YoY growth.

    • Domestic Branded Formulations (DBF) revenue was ₹644 crores, with the base business contributing ₹510 crores.

    • Net debt reduced to ₹2,500 crores, ahead of the year-end target of ₹2,600 crores.

    • Consolidated ROCE increased by 600 bps to 17%; adjusted ROCE (excluding M&A amortization) stands at 23%.

    • Strategic investment of ₹54 crores for a 30% stake in Levim Lifetech to enable vertical integration in biologics.

    • Swiss Parenterals reported Q2 revenue of ₹82 crores and EBITDA of ₹27 crores (33% margin).

    Concerns

    1

    • Insulin Supply Constraints

    What Changed1

    vs Q3 FY25

    Guidance items6 → 5 (-1)

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue₹741 Cr+47%YoY
    2. 02EBITDA₹265 Cr+46%YoY
    3. 03EBITDA Margin35.7%
    4. 04Net Debt₹2,500 Cr
    5. 05ROCE17%

    Segment breakdown

    • Domestic Branded Formulations (DBF)₹644 Cr88.7%
    • Swiss Parenterals₹82 Cr11.3%
    Donut· Share of Revenue

    Guidance & targets

    5
    CategoryTargetPriority
    Revenue
    Domestic Branded Formulations Revenue
    ₹2,600 crores
    		High
    Revenue
    Swiss Parenterals Revenue
    ₹330 crores
    		High
    Margin
    Consolidated EBITDA Margin
    35%
    		High
    Debt
    Net Debt
    ₹2,600 crores
    		High
    Capex
    Capital Expenditure
    ₹100 to 120 crores
    		Medium

    Risks & concerns

    4
    RiskSeverity

    Insulin Supply Constraints

    Supply shortages from MJ and global form-and-fill issues are impacting the Biocon segment growth. — Both acknowledged

    high

    Regulatory Inspection Delays

    Oral solid exports from Ahmedabad depend on EU-GMP/ANVISA inspections targeted for Q4 FY25/Q1 FY26. — Management acknowledged

    medium

    Base Business Slowdown

    Base business growth dropped to 4% in Q2; recovery depends on successful execution of a heavy H2 launch pipeline. — Analyst downplayed

    medium

    Areas of Evasion(1)

    • Specific details on the global insulin supply chain disruption plant location.

    Q&A highlights

    3

    “The H1 growth of the base business is 7% in H1, which is like 10% in Q1 and 4% in Q2... we expect to do 50-50 plus some new products in H2.”

    Clarifies that the organic growth slowed significantly in Q2, making the 9-10% full-year target highly dependent on a flurry of H2 launches.

    asked by Amlan Jyoti Das, Nomura

    2 min read5 chapters

    Detailed Narrative

    01

    Manufacturing Synergies Drive Margin Expansion

    Eris is realizing significant gross margin benefits from shifting production in-house. The Ahmedabad facility now produces 30% of the Derma business, contributing to a base business gross margin expansion from 83% in Q4 FY24 to 86% in Q2 FY25. Additionally, the Bhopal facility is set to commence insulin vial production next month, which is expected to deliver further margin accruals starting Q4 FY25.

    02

    Biologics Strategy and Levim Investment

    The company is aggressively pursuing vertical integration in the ₹15,000 crore Indian biologics market. A strategic ₹54 crore investment for a 30% stake in Levim Lifetech provides Eris with access to a bulk active manufacturing facility and a pipeline including Liraglutide, Streptokinase, and Pegaspargase. This move aims to mitigate supply chain risks and improve economics in the injectable anti-diabetes and oncology segments.

    03

    Biocon Integration and Diabetes Scale

    Post-Biocon integration, Eris has scaled its diabetes business to over ₹1,000 crores per annum with 1,200 Medical Representatives (MRs). The Yield Per Man (YPM) has improved from ₹5.5 lakhs to over ₹7 lakhs. This scale has allowed for better absorption of fixed costs, reducing fixed costs as a percentage of revenue by 509 bps YoY in Q2.

    04

    Swiss Parenterals and CDMO Outlook

    Swiss Parenterals is on track to meet its ₹330 crore revenue guidance for FY25, having achieved ₹155 crore in H1. The business is H2 heavy and maintains a high ROCE exceeding 50%. Management has launched a new EU-focused injectable CDMO business and expects contributions from this and the Oral Solid Dose (OSD) export business to start in FY26.

    05

    Deleveraging and Balance Sheet Strength

    Eris is ahead of its debt repayment schedule, with net debt standing at ₹2,500 crores at the end of Q2 against a year-end target of ₹2,600 crores. Strong operating cash flow, which was 119% of EBITDA in Q2, is supporting this rapid deleveraging while the company continues to invest in R&D and strategic partnerships like Levim.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.